Disc Medicine (IRON) Stock Forecast & Price Target

Compare

550 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

IRON Analyst Ratings

Strong Buy

12 Buy

0 Hold

0 Sell

Based on 12 analysts giving stock ratings to

Disc

Medicine

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

IRON Stock 12 Month Forecast

Average Price Target

$106.50

▲(66.41% Upside)

Based on 12 Wall Street analysts offering 12 month price targets for Disc Medicine in the last 3 months. The average price target is $106.50 with a high forecast of $154.00 and a low forecast of $75.00. The average price target represents a 66.41% change from the last price of $64.00.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"46":"$46","155":"$155","73.25":"$73.3","100.5":"$100.5","127.75":"$127.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":154,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$154.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":106.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$106.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$75.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[46,73.25,100.5,127.75,155],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,80.65,86.2923076923077,91.93461538461538,97.57692307692308,103.21923076923078,108.86153846153846,114.50384615384615,120.14615384615385,125.78846153846155,131.43076923076922,137.07307692307694,142.7153846153846,148.3576923076923,{"y":154,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,80.65,82.63846153846154,84.62692307692308,86.61538461538461,88.60384615384616,90.5923076923077,92.58076923076923,94.56923076923077,96.5576923076923,98.54615384615386,100.53461538461539,102.52307692307693,104.51153846153846,{"y":106.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,80.65,80.21538461538462,79.78076923076924,79.34615384615385,78.91153846153847,78.47692307692309,78.0423076923077,77.6076923076923,77.17307692307692,76.73846153846154,76.30384615384615,75.86923076923077,75.43461538461538,{"y":75,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":55.8,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.18,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.15,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.68,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.73,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51.13,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.97,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.4,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.04,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":86.22,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":91.69,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.41,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":80.65,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$154.00

Average Price Target$106.50

Lowest Price Target$75.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Rami Katkhuda

LifeSci Capital

$100

Buy

56.25%

Upside

Reiterated

02/21/26

Disc Medicine (IRON) Receives a Buy from LifeSci Capital

Douglas Tsao

H.C. Wainwright

$118

Buy

84.38%

Upside

Reiterated

02/17/26

Disc Medicine: Long‑Term Value Intact as Bitopertin Shifts to Lower‑Risk Traditional Approval Path

Derek Archila

Wells Fargo

$109→$78

Buy

21.88%

Upside

Reiterated

02/17/26

Disc Medicine move down Friday 'fair' after bitopertin CRL, says Wells FargoDisc Medicine move down Friday 'fair' after bitopertin CRL, says Wells Fargo

Kristen Kluska

Cantor Fitzgerald

$153→$125

Buy

95.31%

Upside

Reiterated

02/17/26

Disc Medicine price target lowered to $125 from $153 at Cantor FitzgeraldDisc Medicine price target lowered to $125 from $153 at Cantor Fitzgerald

David Nierengarten

Wedbush

$110→$88

Buy

37.50%

Upside

Reiterated

02/17/26

Disc Medicine price target lowered to $88 from $110 at WedbushDisc Medicine price target lowered to $88 from $110 at Wedbush

Sean Laaman

Morgan Stanley

$120→$75

Buy

17.19%

Upside

Reiterated

02/17/26

Analysts Conflicted on These Healthcare Names: Idexx Laboratories (NASDAQ: IDXX), Arrowhead Pharmaceuticals (NASDAQ: ARWR) and Disc Medicine (NASDAQ: IRON)

Evan Seigerman

BMO Capital

$120→$100

Buy

56.25%

Upside

Reiterated

02/17/26

Disc Medicine price target lowered to $100 from $120 at BMO CapitalDisc Medicine price target lowered to $100 from $120 at BMO Capital

Danielle Brill

Truist Financial

―

Buy

―

Reiterated

02/17/26

Analysts Offer Insights on Healthcare Companies: EyePoint Pharmaceuticals (NASDAQ: EYPT), Cochlear (Other OTC: CHEOF) and Disc Medicine (NASDAQ: IRON)

Stephen Willey

Stifel Nicolaus

$125→$110

Buy

71.88%

Upside

Reiterated

02/17/26

Stifel Nicolaus Sticks to Its Buy Rating for Disc Medicine (IRON)

Martin Auster

Raymond James

$78.06→$117

Buy

82.81%

Upside

Reiterated

01/13/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Disc Medicine (NASDAQ: IRON), Nuvalent (NASDAQ: NUVL) and Roche Holding AG (Other OTC: RHHVF)

Tara Bancroft

TD Cowen

―

Buy

―

Reiterated

12/19/25

TD Cowen says Disc Medicine remains confident, bito timeline under CNPV intactTD Cowen says Disc Medicine remains confident, bito timeline under CNPV intact

Roger Song

Jefferies

$154

Buy

140.63%

Upside

Reiterated

12/19/25

Jefferies sees 'overreaction' to article on Disc Medicine's EPP approvabilityJefferies sees 'overreaction' to article on Disc Medicine's EPP approvability

Thomas Smith

Leerink Partners

$85→$100

Buy

56.25%

Upside

Reiterated

10/17/25

Leerink Partners Keeps Their Buy Rating on Disc Medicine (IRON)

Greg Harrison

Scotiabank

$75

Buy

17.19%

Upside

Reiterated

06/17/25

Scotiabank Sticks to Their Buy Rating for Disc Medicine (IRON)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Rami Katkhuda

LifeSci Capital

$100

Buy

56.25%

Upside

Reiterated

02/21/26

Disc Medicine (IRON) Receives a Buy from LifeSci Capital

Douglas Tsao

H.C. Wainwright

$118

Buy

84.38%

Upside

Reiterated

02/17/26

Disc Medicine: Long‑Term Value Intact as Bitopertin Shifts to Lower‑Risk Traditional Approval Path

Derek Archila

Wells Fargo

$109→$78

Buy

21.88%

Upside

Reiterated

02/17/26

Disc Medicine move down Friday 'fair' after bitopertin CRL, says Wells FargoDisc Medicine move down Friday 'fair' after bitopertin CRL, says Wells Fargo

Kristen Kluska

Cantor Fitzgerald

$153→$125

Buy

95.31%

Upside

Reiterated

02/17/26

Disc Medicine price target lowered to $125 from $153 at Cantor FitzgeraldDisc Medicine price target lowered to $125 from $153 at Cantor Fitzgerald

David Nierengarten

Wedbush

$110→$88

Buy

37.50%

Upside

Reiterated

02/17/26

Disc Medicine price target lowered to $88 from $110 at WedbushDisc Medicine price target lowered to $88 from $110 at Wedbush

Sean Laaman

Morgan Stanley

$120→$75

Buy

17.19%

Upside

Reiterated

02/17/26

Analysts Conflicted on These Healthcare Names: Idexx Laboratories (NASDAQ: IDXX), Arrowhead Pharmaceuticals (NASDAQ: ARWR) and Disc Medicine (NASDAQ: IRON)

Evan Seigerman

BMO Capital

$120→$100

Buy

56.25%

Upside

Reiterated

02/17/26

Disc Medicine price target lowered to $100 from $120 at BMO CapitalDisc Medicine price target lowered to $100 from $120 at BMO Capital

Danielle Brill

Truist Financial

―

Buy

―

Reiterated

02/17/26

Analysts Offer Insights on Healthcare Companies: EyePoint Pharmaceuticals (NASDAQ: EYPT), Cochlear (Other OTC: CHEOF) and Disc Medicine (NASDAQ: IRON)

Stephen Willey

Stifel Nicolaus

$125→$110

Buy

71.88%

Upside

Reiterated

02/17/26

Stifel Nicolaus Sticks to Its Buy Rating for Disc Medicine (IRON)

Martin Auster

Raymond James

$78.06→$117

Buy

82.81%

Upside

Reiterated

01/13/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Disc Medicine (NASDAQ: IRON), Nuvalent (NASDAQ: NUVL) and Roche Holding AG (Other OTC: RHHVF)

Tara Bancroft

TD Cowen

―

Buy

―

Reiterated

12/19/25

TD Cowen says Disc Medicine remains confident, bito timeline under CNPV intactTD Cowen says Disc Medicine remains confident, bito timeline under CNPV intact

Roger Song

Jefferies

$154

Buy

140.63%

Upside

Reiterated

12/19/25

Jefferies sees 'overreaction' to article on Disc Medicine's EPP approvabilityJefferies sees 'overreaction' to article on Disc Medicine's EPP approvability

Thomas Smith

Leerink Partners

$85→$100

Buy

56.25%

Upside

Reiterated

10/17/25

Leerink Partners Keeps Their Buy Rating on Disc Medicine (IRON)

Greg Harrison

Scotiabank

$75

Buy

17.19%

Upside

Reiterated

06/17/25

Scotiabank Sticks to Their Buy Rating for Disc Medicine (IRON)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Disc Medicine

3 Months

xxx

Success Rate

17/21 ratings generated profit

Average Return

+25.10%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 80.95% of your transactions generating a profit, with an average return of +25.10% per trade.

1 Year

Thomas SmithLeerink Partners

Success Rate

17/21 ratings generated profit

Average Return

+31.67%

reiterated a buy rating 4 months ago

Copying Thomas Smith's trades and holding each position for 1 Year would result in 80.95% of your transactions generating a profit, with an average return of +31.67% per trade.

2 Years

xxx

Success Rate

21/21 ratings generated profit

Average Return

+56.94%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +56.94% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

IRON Analyst Recommendation Trends

Rating

Oct 25

Nov 25

Dec 25

Jan 26

Feb 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, IRON has received 37 Buy Ratings, 28 Hold Ratings, and 0 Sell Ratings. IRON average Analyst price target in the past 3 months is 106.50.

Each month's total comprises the sum of three months' worth of ratings.

IRON Financial Forecast

IRON Earnings Forecast

Next quarter’s earnings estimate for IRON is -$1.71 with a range of -$2.07 to -$1.50. The previous quarter’s EPS was -$1.77. IRON beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year IRON has Performed in-line its overall industry.

No data currently available

IRON Sales Forecast

Next quarter’s sales forecast for IRON is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. IRON beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year IRON has Performed in-line its overall industry.

IRON Stock Forecast FAQ

What is IRON’s average 12-month price target, according to analysts?

Based on analyst ratings, Disc Medicine’s 12-month average price target is 106.50.

What is IRON’s upside potential, based on the analysts’ average price target?

Disc Medicine has 66.41% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is IRON a Buy, Sell or Hold?

Disc Medicine has a consensus rating of Strong Buy which is based on 12 buy ratings, 0 hold ratings and 0 sell ratings.

What is Disc Medicine’s price target?

The average price target for Disc Medicine is 106.50. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $154.00 ,the lowest forecast is $75.00. The average price target represents 66.41% Increase from the current price of $64.

What do analysts say about Disc Medicine?

Disc Medicine’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.

How can I buy shares of IRON?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Disc Medicine (IRON) Stock Forecast & Price Target

IRON Analyst Ratings

IRON Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Disc Medicine

IRON Analyst Recommendation Trends

IRON Financial Forecast

IRON Earnings Forecast

IRON Sales Forecast

IRON Stock Forecast FAQ

Detailed List of Analyst Forecasts